Literature DB >> 3992044

Adenosine deaminase inhibition and myocardial adenosine metabolism during ischemia.

P W Achterberg, J W de Jong.   

Abstract

It is generally assumed that myocardial adenine nucleotides are broken down (e.g., during ischemia) via AMP----adenosine----inosine, but contribution of the pathway AMP----IMP----inosine cannot be excluded. The catabolism of exogenously added adenosine (1-20 microM) was studied in isolated rat hearts. All catabolites (i.e., inosine, hypoxanthine, xanthine, and uric acid) were measured together with nonmetabolized adenosine. Even at low (1 microM) adenosine concentrations, deamination accounted for 60% of adenosine disappearing from the perfusate. The adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) (5 and 50 microM) was infused together with adenosine (5 microM). These two concentrations of EHNA inhibited deamination of exogenous adenosine by 65 and 91%, respectively. When hearts were made ischemic by reduction of perfusion pressure, addition of EHNA raised the adenosine release from 1.4 to 9.8 nmole/min per gram wet wt., but surprisingly, the release of inosine and oxypurines (8 nmole/min per g wet wt.) did not change. These results suggest that considerable breakdown of myocardial adenine nucleotides can occur via the AMP----IMP----inosine pathway instead of AMP----adenosine----inosine. The rate of total purine release is probably not a good measure of intracellular adenosine formation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3992044

Source DB:  PubMed          Journal:  Adv Myocardiol        ISSN: 0270-4056


  2 in total

1.  Effect of endogenous adenosine augmentation on ischemia and reperfusion injury to the liver.

Authors:  S Zhang; M B Jin; Y Zhu; N Ishizaki; H Tanaka; V M Subbotin; R G Lee; T E Starzl; S Todo
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

2.  Transmural differences in the postischemic recovery of cardiac energy metabolism.

Authors:  S M Humphrey; M A Vanderwee; J B Gavin
Journal:  Am J Pathol       Date:  1988-04       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.